We are comparing Sutro Biopharma Inc. (NASDAQ:STRO) and Prothena Corporation plc (NASDAQ:PRTA) on their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation. They both are Biotechnology companies, competing one another.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sutro Biopharma Inc.||11||5.28||N/A||-1.66||0.00|
|Prothena Corporation plc||11||427.82||N/A||-3.20||0.00|
Demonstrates Sutro Biopharma Inc. and Prothena Corporation plc earnings per share (EPS), gross revenue and valuation.
Table 2 has Sutro Biopharma Inc. and Prothena Corporation plc’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Sutro Biopharma Inc.||0.00%||0%||0%|
|Prothena Corporation plc||0.00%||-38.4%||-25%|
Sutro Biopharma Inc. has a Current Ratio of 5.7 and a Quick Ratio of 5.7. Competitively, Prothena Corporation plc’s Current Ratio is 27.9 and has 27.9 Quick Ratio. Prothena Corporation plc’s better ability to pay short and long-term obligations than Sutro Biopharma Inc.
Insider and Institutional Ownership
Sutro Biopharma Inc. and Prothena Corporation plc has shares owned by institutional investors as follows: 73.1% and 92.7%. 21.23% are Sutro Biopharma Inc.’s share owned by insiders. On the other hand, insiders owned about 90.1% of Prothena Corporation plc’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Sutro Biopharma Inc.||1.9%||-4.09%||13.27%||5.52%||0%||24.94%|
|Prothena Corporation plc||-6.49%||-8.86%||-7.42%||-20.34%||-36.28%||-9.13%|
For the past year Sutro Biopharma Inc. had bullish trend while Prothena Corporation plc had bearish trend.
Sutro Biopharma Inc. beats on 4 of the 7 factors Prothena Corporation plc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in DÃºn Laoghaire, Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.